Scientists Resurrect Ancient Cannabis Enzymes With Major Medical Promise

Million-Year-Old Enzymes Could Transform Cannabinoid Medicine

Scientists at Wageningen University & Research in the Netherlands have done something remarkable: they resurrected ancient cannabis enzymes that existed millions of years ago and, in doing so, uncovered a practical pathway to producing rare cannabinoids that today's cannabis plants can barely make.

The study, published in early 2026, provides the first experimental proof showing how cannabis evolved the ability to produce its most famous compounds—THC, CBD, and CBC. More importantly for patients and the pharmaceutical industry, the ancient enzyme versions turned out to be more versatile and easier to work with than their modern counterparts.

How the Research Worked

The Wageningen team used a technique called ancestral sequence reconstruction, essentially a form of molecular archaeology. By analyzing the genetic sequences of modern cannabis enzymes alongside those of related plant species, the researchers computationally reconstructed what the enzymes likely looked like at various points in evolutionary history, then synthesized and tested those ancient proteins in the lab.

What they found rewrote the conventional understanding of cannabinoid evolution.

From Generalist to Specialist

Modern cannabis plants produce cannabinoids through highly specialized enzymes. THCA synthase makes THCA (the precursor to THC), CBDA synthase makes CBDA (the precursor to CBD), and CBCA synthase makes CBCA (the precursor to CBC). Each enzyme does one job.

But the ancestral versions told a different story. The earliest reconstructed enzyme produced none of these cannabinoids at all. A later version—representing a more recent evolutionary ancestor—functioned as a generalist, capable of synthesizing all three cannabinoid acids simultaneously.

Over millions of years, evolution fine-tuned this generalist enzyme into the specialized forms found in today's cannabis varieties. The plant essentially traded versatility for efficiency, optimizing each enzyme for a single cannabinoid output.

Why This Matters for Medicine

The practical implications are significant, particularly for cannabichromene (CBC).

CBC is one of the most promising therapeutic cannabinoids identified to date. Research has shown it possesses potent anti-inflammatory properties, and studies suggest potential applications in pain management, neuroprotection, and even mood regulation. Unlike THC, CBC doesn't produce psychoactive effects, making it appealing for pharmaceutical development.

The problem is that modern cannabis plants produce very little CBC naturally. The CBCA synthase enzyme in today's varieties is relatively inefficient, and commercial cannabis breeding has focused almost exclusively on maximizing THC or CBD production. Getting meaningful quantities of CBC from plants is impractical at pharmaceutical scale.

The ancient generalist enzyme changes that equation. Because it produces CBC alongside THC and CBD, it offers a direct route to CBC production that doesn't depend on modern cannabis cultivation.

The Yeast Factory Approach

Here's where the research gets commercially relevant. The ancestral enzymes are promising tools for producing cannabinoids in microorganisms—a method that's increasingly important for medicinal applications.

The concept is straightforward: engineers insert cannabis genes into yeast, and the yeast builds cannabinoid acids from sugars during fermentation. Companies could produce cannabinoids in steel tanks under tight, controlled conditions, eliminating the variability inherent in agricultural cultivation.

This biosynthetic approach has been under development for years, but the ancient enzymes offer distinct advantages. They tend to be more robust and stable than modern versions, functioning well across a wider range of conditions. For industrial fermentation, where precise environmental control matters enormously, this robustness translates directly to more consistent output and lower production costs.

Several biotech companies are already working on yeast-based cannabinoid production. The availability of versatile ancestral enzymes could accelerate these efforts, particularly for rare cannabinoids that are difficult to source from plants.

Over 70 Cannabis Studies Published in 2026

The Wageningen enzyme study is part of a broader surge in cannabis science. Over 70 cannabis-related studies have been published in 2026 alone, covering a remarkable range of medical applications.

Notable findings this year include research showing CBD and CBG may help reverse fatty liver disease by altering how liver cells handle energy metabolism. Another study found that a cannabis-based herbal formula performed comparably to lorazepam in treating chronic insomnia, without the dependency risks associated with benzodiazepines.

Clinical trials have also reported that CBD suppositories reduced menstrual and pelvic pain symptoms, while separate research demonstrated CBD's ability to reduce breast cancer cell viability through pathways involving oxidative stress and mitochondrial dysfunction.

New York State launched its first state-designed clinical study examining how oral doses of CBD and THC affect quality of life in adults with inflammatory bowel disease, adding government-funded research to the growing body of cannabinoid science.

The Rescheduling Effect on Research

The timing of these scientific advances coincides with the federal rescheduling of cannabis from Schedule I to Schedule III, announced in April 2026. While the rescheduling primarily affects medical cannabis regulation and business taxation, it also has implications for research.

Schedule III classification reduces some of the bureaucratic barriers that have historically made cannabis research difficult in the United States. Researchers may find it easier to obtain material, secure funding, and conduct clinical trials—though significant regulatory requirements remain.

The upcoming DEA hearing on June 29, which will evaluate broader rescheduling, could further expand research opportunities if it leads to additional changes in cannabis's legal status.

What Comes Next

The Wageningen team's work opens several research directions. Understanding the evolutionary trajectory of cannabinoid enzymes could help identify additional ancestral variants with useful properties. The generalist enzymes might be further engineered to optimize production of specific rare cannabinoids beyond CBC, including cannabigerol (CBG), cannabinol (CBN), and lesser-studied compounds.

For the cannabis industry, the research underscores a broader trend: the future of cannabinoid medicine may depend as much on biotechnology and synthetic biology as it does on traditional cultivation. As our understanding of cannabis biochemistry deepens, the gap between what nature provides and what science can produce continues to narrow.

The ancient enzymes, dormant for millions of years, may prove to be exactly what modern medicine needs.